Jodi Segal, MD

Professional Titles

• Co-Director, Center for Drug Safety and Effectiveness
• Associate Director, Center for Health Services and Outcomes Research
• Director, Pharmacoepidemiology Program

Primary Academic Title

Professor of Medicine

Background

Centers and Institutes

• Drug Safety and Effectiveness, Center for
• Health Services and Outcomes Research, Center for
• Welch Center for Prevention, Epidemiology, and Clinical Research

Research Interests

Comparative effectiveness research, Evidence synthesis, High-value healthcare, Pharmacoepidemiology

Lab Website

Jodi Segal Lab

• Research in the Jodi Segal Lab focuses on developing methodologies to use observational data to understand the use of new drugs, particularly drugs for treating diabetes, blood disorders and osteoporosis. We apply advanced methods for evidence-based review and meta-analysis, and--in collaboration with Johns Hopkins biostatisticians--we have developed new methodologies for observational research (using propensity scores to adjust for covariates that change over time) and methods to account for competing risks and heterogeneity of treatment effects in analyses.

Research Summary

Dr. Segal’s research interests include developing methodology to use observational data to understand the use of new drugs, particularly drugs for treatment of diabetes, blood disorders and osteoporosis. She is an experienced clinical epidemiologist and health services researcher with skills in applying advanced methods for evidence-based review and meta-analysis, and in collaboration with her colleagues in biostatistics, has developed new methodologies for observational research (using propensity scores to adjust for covariates which change over time) and methods to account for competing risks and heterogeneity of treatment effects in analyses.

PubMed

http://www.ncbi.nlm.nih.gov/pubmed?term=segal%20jb%5BAuthor%5D%20NOT%20Segal%2C%20Jessica%5BFull%20Author%20Name%5D&cmd=DetailsSearch

Selected Publications

• Segal JB, Bridges JF, Chang HY, Chang E, Nassery N, Weiner J, Chan KS. Identifying Possible Indicators of Systematic Overuse of Health Care Procedures With Claims Data. Med Care. 2013 Dec 26. [Epub ahead of print] PMID: 24374418

• Segal JB, Maruthur NM. “Initial therapy for diabetes mellitus.” JAMA Intern Med. 2014 Dec;174(12):1962-3

• Segal JB, Nassery N, Chang HY, Chang E, Chan K, Bridges JF. “An index for measuring overuse of health care resources with Medicare claims.” Med Care. 2015 Mar;53(3):230-6.

• Bridges JFP, Berger Z, Austin M, Nassery N, Sharma R, Chelladurai Y, Karmarkar TD, Segal JB. “Public reporting of cost measures in health: an environmental scan of current practices and assessment of consumer centeredness [Internet].” Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Mar

• Chan KS, Chang E, Nassery N, Chang HY, Segal JB. The state of overuse measurement: a critical review. Med Care Res Rev. 2013 Oct;70(5):473-96. doi: 10.1177/1077558713492202. Epub 2013 Jun 26. PMID: 23804290 

• Chang HY, Richards TM, Clark JM, Weiner JP, Segal JB. Change in claims-based diabetes medications is a diabetes improvement indicator. Am J Manag Care. 2013 Jul;19(7):572-8. PMID: 23919420 [PubMed - in process]

• Erekosima N, Suarez-Cuervo C, Ramanathan M, Kim JM, Chelladurai Y, Segal JB, Lin SY. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: A Systematic Review. Laryngoscope. 2013 Jul 6. doi: 10.1002/lary.24295. [Epub ahead of print] PMID: 23832632

• Gudzune KA, Lau BD, Hutfless S, Boult C, Segal JB. Strategies To Prevent Weight Gain in Adults: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 97 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Jun. PMID: 24027797

• Haut ER, Garcia LJ, Shihab HM, Brotman DJ, Stevens KA, Sharma R, Chelladurai Y, Akande TO, Shermock KM, Kebede S, Segal JB, Singh S. The Effectiveness of Prophylactic Inferior Vena Cava Filters in Trauma Patients: A Systematic Review and Meta-analysis. JAMA Surg. 2013 Nov 6. doi: 10.1001/jamasurg.2013.3970. [Epub ahead of print] PMID: 24195920

• Huang YL, Moon J, Segal JB. “A comparison of active adverse event surveillance systems worldwide.” Drug Saf. 2014 Aug;37(8):581-96

• Naik RP, Streiff MB, Haywood C Jr, Segal JB, Lanzkron S. “Venous thromboembolism incidence in the cooperative study of sickle cell disease.” J Thromb Haemost. 2014 Dec;12(12):2010-6

• Nassery N, Segal JB, Chang E, Bridges JF. “Systematic overuse of healthcare services: a conceptual model.” Appl Health Econ Health Policy. 2015 Feb;13(1):1-6

• Raebel MA, Xu S, Goodrich GK, Schroeder EB, Schmittdiel JA, Segal JB, O'Connor PJ, Nichols GA, Lawrence JM, Kirchner HL, Elston Lafata J, Butler M, Newton KM, Steiner JF. Initial Antihyperglycemic Drug Therapy Among 241 327 Adults With Newly Identified Diabetes From 2005 Through 2010: A Surveillance, Prevention, and Management of Diabetes Mellitus (SUPREME-DM) Study. Ann Pharmacother. 2013 Oct;47(10):1280-91. doi: 10.1177/1060028013503624. PMID: 24259692

• Romanelli RJ, Segal JB. “Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.” J Gen Intern Med. 2014 Oct;29(10):1372-8

• Romanelli RJ, Jukes T, Segal JB. “Compliance after switching from branded to generic statins.” Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1093-100

• Romano MJ, Segal JB, Pollack CE. “The association between continuity of care and the overuse of medical procedures.” JAMA Intern Med. 2015 Jul;175(7):1148-54

• Schmittdiel JA, Raebel MA, Dyer W, Xu S, Goodrich GK, Schroeder EB, Segal JB, O' Connor PJ, Nichols GA, Lawrence JM, Kirchner HL, Karter AJ, Lafata JE, Butler MG, Steiner JF. “Prescription medication burden in patients with newly diagnosed diabetes: a SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) study.” J Am Pharm Assoc (2003). 2014 Jul-Aug;54(4):374-82

• Singh S, Haut ER, Brotman DJ, Sharma R, Chelladurai Y, Shermock KM, Kebede S, Stevens KA, Prakasa KR, Shihab HM, Akande TO, Zeidan AM, Garcia LJ, Segal JB. Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 May. PMID: 23844446

• Snyder CF, Jensen RE, Segal JB, Wu AW. Patient-reported outcomes (PROs): putting the patient perspective in patient-centered outcomes research. Med Care. 2013 Aug;51(8 Suppl 3):S73-9. doi: 10.1097/MLR.0b013e31829b1d84. PMID: 23774513

• Wu Y, Lau BD, Bleich S, Cheskin L, Boult C, Segal JB, Wang Y. Future Research Needs for Childhood Obesity Prevention Programs: Identification of Future Research Needs From Comparative Effectiveness Review No. 115 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Jun. PMID: 24027795

Courses & Syllabi

• Pharmacoepidemiology Methods, Johns Hopkins Bloomberg School of Public Health, 340.682.01, 1/1/15
• Pharmacoepidemiology Methods, Johns Hopkins Bloomberg School of Public Health, 340.682.81, 1/1/15
• Introduction to Comparative Effectiveness and Outcomes Research, Johns Hopkins Bloomberg School of Public Health, 312.693.81, 1/1/15

Honors

• Phi Beta Kappa
• Alpha Omega Alpha
• Best Abstract (Measuring Safety, Quality and Value category), Academy Health Annual Research Meeting, 1/1/15

Professional Activities

• Eastern Region of the American Federation for Medical Research (AFMR), Chair-Elect, 1/1/07
• Johns Hopkins, Leadership Program for Women Faculty, 1/1/10
• Johns Hopkins Division of General Internal Medicine, Fellowship Advisory Committee
• Journal of General Internal Medicine, Deputy Editor, 1/1/07
• Primary Care and Health Services Research Training Program, Principal Investigator